Management Team

Symbol Logo for Blue.png
Tom Douthitt Head shot_edited_edited.jpg

Tom Douthitt, CEO 

Tom Douthitt joins Caeli bringing over 30 years domestic international MedTech leadership, serving as CEO/GM/VP, with emerging growth start-ups and Fortune 500 companies. He started his career as an acquisitions analyst with Eli Lilly’s Medical Device Division which later split off to become Guidant Corp. He rose through several managerial roles at Guidant before leaving to become GM for Abbott Vascular’s Cardiovascular Division. He established a solid track record bringing disruptive medical technologies to market, with demonstrated success leading sales, marketing, business development, product development, and clinical trial management that created value and sustainable market share. He has been part of Sr mgmt teams at 5 start-ups advancing technologies from concept to commercialization. He has seven issued patents and has raised over $70Million across 4 start-ups, leading his last 3 companies to successful exits totaling >$500Million.

Chief Executive Officer

Tom Douthitt

Small Title

Mohamed_edited.png

Dr. Mohamed Zayed, CMO

Dr. Zayed is an American Board of Surgery certified vascular surgeon and a fellow of the American College of Surgeons. He treats a breadth of arterial and venous medical conditions and is an NIH-funded research scientist who is developing novel therapeutics for both arterial and venous pathology (zayedlab.wustl.edu). He is a co-founder of Caeli Vascular, Inc., and one of the inventors of the technology.  He is extensively involved in the development and pre-clinical efforts for our SUMMIT technology, and he manages our Medical Advisory Board

Mohamed Zayed, MD, PhD, FACS

Chief Medical Officer

Stacey_edited.jpg

Stacey Liekweg, COO

Stacey is a co-Founder of Caeli Vascular and has guided development of the technology since the company’s inception in 2019.  She is a seasoned healthcare executive with over 30 years of experience who has successfully led teams at large companies, and start-ups within the medtech space; and has served as Administrator for several academic healthcare institutions. Prior to starting Caeli, Stacey was CEO of Immunovalent Therapeutics Inc., a startup developing cancer immunotherapy biomarkers. Stacey brings to Caeli tremendous experience managing multiple functional areas as well as an exceptional understanding of institutional and payor needs.

Chief Operating Officer

Mohamed_edited.png

Dr. Mohamed Zayed, CMO

Dr. Zayed is an American Board of Surgery certified vascular surgeon and a fellow of the American College of Surgeons. He treats a breadth of arterial and venous medical conditions and is an NIH-funded research scientist who is developing novel therapeutics for both arterial and venous pathology (zayedlab.wustl.edu). He is a co-founder of Caeli Vascular, Inc., and one of the inventors of the technology.  He is extensively involved in the development and pre-clinical efforts for our SUMMIT technology, and he manages our Medical Advisory Board

Mohamed Zayed, MD, PhD, FACS

Chief Medical Officer

Stacey Liekweg

RichVanBibber Headshot_edited_edited.jpg

Dr. Rich Van Bibber, Sr. VP Clinical & Regulatory Affairs

Dr. Van Bibber is an accomplished med-tech executive with academic training in Physiology and Biophysics and 25 years experience in multiple aspects of regulated medical device product development. He has held leadership positions in FDA regulated environments for class II and III cardiac and cardiovascular devices, including catheter-based therapies. Rich has planned & executed multinational pre-clinical and clinical trials, developed & submitted regulatory filings for 510(k), PMA, HDE and CE Mark, and has published and presented the work he has accomplished to support commercial efforts. He has played key management roles at five start-up companies helping to lead his last two to successful exits.

Rich Van Bibber, PhD

Senior Vice President Clinical & Regulatory Affairs

Board of Directors

Symbol Logo for Blue.png
Tom Douthitt Head shot_edited_edited.jpg

Tom Douthitt, CEO 

Tom Douthitt joins Caeli bringing over 30 years domestic international MedTech leadership, serving as CEO/GM/VP, with emerging growth start-ups and Fortune 500 companies. He started his career as an acquisitions analyst with Eli Lilly’s Medical Device Division which later split off to become Guidant Corp. He rose through several managerial roles at Guidant before leaving to become GM for Abbott Vascular’s Cardiovascular Division. He established a solid track record bringing disruptive medical technologies to market, with demonstrated success leading sales, marketing, business development, product development, and clinical trial management that created value and sustainable market share. He has been part of Sr mgmt teams at 5 start-ups advancing technologies from concept to commercialization. He has seven issued patents and has raised over $70Million across 4 start-ups, leading his last 3 companies to successful exits totaling >$500Million.

CEO, Caeli Vascular

Eric_edited.jpg

Dr. Eric Leuthardt 

Dr. Leuthardt is a Co-Founder of Caeli Vascular whose extensive startup experience, combined with academic rigor, has enabled him to evaluate and lead a broad array of medical technology efforts and investments. He is one of the inventors of the SUMMIT technology and is the author of over 1,800 patent filings with over 600 issued. In addition to his academic appointment, he serves as a Venture Partner for E15 Ventures. 

Eric Leuthardt, MD

Chief, Division of Neurotechnology, Washington University, School of Medicine in St. Louis

Josh_edited.jpg

John Hardin, Independent Director

John Hardin is the former CEO of Caeli Vascular and has more than 30 years of commercial leadership experience in the medical device field. In his experience, Mr. Hardin has held leadership roles at ev3, Inc, Medtronic, Baxter and American Hospital Supply. His experience touches the interventional neuromuscular, interventional radiology, interventional cardiology, vascular surgery, general surgery and electrophysiology market spaces.

John Hardin

Independent Director

phil-lang_edited_edited_edited.jpg

Philip Liang, E15 Ventures 

Phil Liang is an engineer, designer, and serial entrepreneur turned investor. He is Founder and Managing Partner of E15VC a global deep-technology investment firm, focused on Seed through later stage venture; investments include, Auris Health (Acquired by J&J), Vicarious Surgical (NYSE: RBOT), Caeli Vascular and Frankie Health.

Philip Liang

Managing Partner, E15 Ventures

Tom Douthitt

Founders

Symbol Logo for Blue.png
Eric_edited.jpg

Eric Leuthardt, MD

Chief, Division of Neurotechnology, Washington University, School of Medicine in St. Louis

Josh_edited.jpg

John Hardin

Independent Director

Stacey_edited.jpg

Chief Operating Officer, Caeli Vascular

Guy_edited.jpg

Guy Genin

Harold and Kathleen Faught Professor of Mechanical Engineering

Mechanical Engineering & Materials Science

Mohamed_edited.png

Mohamed Zayed, MD, PhD, FACS

Associate Professor of Surgery and Radiology
Section of Vascular Surgery
Director, Zayed Lab & Vascular Surgery BioBank

Stacey Liekweg